ISDA

Deposition Date 2016-05-20

Release Date 2016-07-06

Last Version Date 2024-03-06

Entry Detail

PDB ID:

5K4I

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Crystal Structure of ERK2 in complex with compound 22

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.76 Å

R-Value Free:

0.23

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Mitogen-activated protein kinase 1
Gene (Uniprot):MAPK1
Chain IDs:A
Chain Length:352
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P28482 Pfam ID:PF00069 EC:2.7.11.24

Ligand Molecules

6QB

EDO

Primary Citation

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Blake, J.F, Burkard, M, Chan, J, Chen, H, Chou, K.J, Diaz, D, Dudley, D.A, Gaudino, J.J, Gould, S.E, Grina, J, Hunsaker, T, Liu, L, Martinson, M, Moreno, D, Mueller, L, Orr, C, Pacheco, P, Qin, A, Rasor, K, Ren, L, Robarge, K, Shahidi-Latham, S, Stults, J, Sullivan, F, Wang, W, Yin, J, Zhou, A, Belvin, M, Merchant, M, Moffat, J, Schwarz, J.B.Show

J.Med.Chem. 59 5650 5660 (2016)

PMID: 27227380 DOI: 10.1021/acs.jmedchem.6b00389

Abstact

The extracellular signal-regulated kinases ERK1/2 represent an essential node within the RAS/RAF/MEK/ERK signaling cascade that is commonly activated by oncogenic mutations in BRAF or RAS or by upstream oncogenic signaling. While targeting upstream nodes with RAF and MEK inhibitors has proven effective clinically, resistance frequently develops through reactivation of the pathway. Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures